NICE TA Adherence list September 2013 Drug Indication NICE Approval Release Date Formulary review Ocriplasmin Vitreomacular Traction Approved 23/10/2013 Yes Aflibercept ( Eylea) Wet-age related Macular degeneration Approved 24/07/2013 Yes Eltrombopag Idiopathic thrombocytopenia purpura Approved 24/07/2013 Yes Aripiprazole (oral) Bipolar Disorder (children 13yrs & over) Approved 24/07/2013 Yes Mirabegron Overactive Bladder Approved 26/06/2013 Yes Dapagliflozin Combination thearpy Type2 diabetes Approved 26/06/2013 Yes Rivaroxaban Pulmonary embolism & preventing recurrent venous thromboembolism Approved 26/06/2013 Yes Ranibizumab visual impairment caused by macular oedema secondary to retinal veil occlusion Approved 22/05/2013 Yes Kyphoplasty Vertebral Fractures Approved 25/04/2013 Yes Pirfenidone Idiopathic pulmonary fibrosis Approved 24/04/2013 Yes Abatacept RA (first TNF) Approved 24/04/2013 Yes Vertebroplasty Vertebral Fractures Approved 24/04/2013 Yes Omalizumab Asthma - over 12yo & adults Approved 24/04/2013 Yes Omalizumab Asthma - 6-11yo Approved 24/04/2013 Yes Colistimethate Sodium Cystic Fibrosis (pseudomonas lung infection) Approved 27/03/2013 Yes
Tobramycin Cystic Fibrosis (pseudomonas lung infection) Approved 27/03/2013 Yes Ranibizumab Diabetic macular oedema Approved 27/02/2013 Yes Apixaban Stroke & Systemic embolism Approved 27/02/2013 Yes Verumafenib Locally Adv. Or metastatic BRAF V600 mutation-positive unresectable metastatic Approved 12/12/2012 Yes Ipilimumab Metastatic melanoma Approved 12/12/2012 Yes Ivabradine Heart Failure II - IV Approved 28/11/2012 Yes Mannitol Cystic Fibrosis Approved 28/11/2012 Yes Botulinum toxin A Chronic migraine Approved 27/11/2012 Yes Denosumab Bone Metastases for solid tumours Approved 24/10/2012 Yes Alteplase Acute ischaemic stoke Approved 26/09/2012 Yes Rivaroxaban deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Approved 25/07/2012 Yes Abiraterone (Zytiga) Metastatic Castration resistant Prostate Ca Approved 27/06/2012 Yes Erlotinib NSCLC with EGFR activating mutations TA258 Approved 27/06/2012 Yes Rivaroxaban Stroke prevention in AF Approved 23/05/2012 Yes Bocepravir Genotype 1 chronic Hepatitis C Approved 25/04/2012 Yes Telaprevir Genotype 1 chronic Hepatitis C Approved 25/04/2012 Yes
Dexamethasone implant (Ozurdex) Macular oedema associated with retinal vein occlusion Approved 27/07/2011 Yes Bortezomib Multiple Myeloma (1st line) Approved 27/07/2011 Yes Thalidomide Mulitple myeloma (1st line) Approved 27/07/2011 Yes Rituximab Follicular NHL (maintenance) Approved 22/06/2011 Yes Golimumab Rheumatoid arthritis (2nd line ) Approved 22/06/2011 Yes Naftidrofuryl oxalate Intermiittent claudication associated with peripheral vasular disease Approved 25/05/2011 Yes Romiplostim Idiopathic thrombocytopenia purpura Approved 27/04/2011 Yes Golimumab Psoriatic arthritis Approved 27/04/2011 Yes Rivastigmine Alzheimer's disease Approved 23/03/2011 Yes Rivastigmine (patch) Alzheimer's disease Approved 23/03/2011 Yes Donepezil Alzheimer's disease Approved 23/03/2011 Yes Galantamine Alzheimer's disease Approved 23/03/2011 Yes Azacitidine Myelodysplastic syndrome Approved 23/03/2011 Yes Memantine Alzheimer's disease Approved 23/03/2011 Yes Bendamustine CLL (1st line) Approved 23/02/2011 Yes Pazopanib Metastatic renal cell Ca (1st line) Approved 23/02/2011 Yes Aripiprazole (oral) Schizophrenia (15-17yo) Approved 26/01/2011 Yes Raloxifene Secondary prevention of osteoporosis Approved 26/01/2011 Yes Teriparatide Osteoporosis Approved 26/01/2011 Yes Alendronate Secondary prevention Approved 26/01/2011 Yes
Panitumumab Metastatic colorectal Ca (2nd line) Not approved 25/01/2012 No Dasatinib CML dasatinib, nilotinib, imatinib (intolerant, resistant) not approved 13/01/2012 No Imatinib CML dasatinib, nilotinib, imatinib (intolerant, resistant) Not approved 13/01/2012 No Fulvestrant Breast Ca Not approved 14/12/2011 No Panitumumab Metastatic colorectal Ca (2nd line) Terminated 14/12/2011 No Bendamustine Indolent NHL Not approved 27/10/2011 No Agomelatine Depression Not approved 27/07/2011 No Erlotinib NSCLC - maintenance Not approved 29/06/2011 No Golimumab RA Terminated 22/06/2011 No Cilostazol Intermiittent claudication associated with peripheral vasular disease Not approved 25/05/2011 No Inositol nicotinate Intermiittent claudication associated with peripheral vasular disease Not Approved 25/05/2011 No Pentoxifylline Intermiittent claudication associated with peripheral vasular disease Not approved 25/05/2011 No Trabectedin Relapsed ovarian Ca Not approved 27/04/2011 No Everolimus Advanced RCC (2nd line) Not approved 19/04/2011 No Bevacizumab Metastatic breast Ca Not approved 23/02/2011 No Raloxifene Primary prevention of osteoporosis Not approved 26/01/2011 No
Bevacizumab Metastatic colorectal Ca Not approved 15/12/2010 No Trastuzumab HER2 +ve metastatic gastric Ca Not approved 24/11/2010 No Ofatumumab CLL Not approved 27/10/2010 No Fesoterodine Non-Hodgkin's lymphoma Not approved 27/10/2010 No Imatinib GIST (adjuvant) Not approved 25/08/2010 No Sorafenib Hepatocellular Ca Not approved 26/05/2010 No Sorafenib Renal cell Ca Not approved 29/08/2009 No Sunitinib Renal cell Ca (2nd line) Not approved 29/08/2009 No Temsirolimus Renal cell Ca Not approved 29/08/2009 No Bevacizumab Renal cell Ca Not approved 29/08/2009 No Cetuximab Head & neck Ca (recurrent or metastatic) Not approved 24/06/2009 No Amantadine Treatment of influenza Not approved 25/02/2009 No Amantadine Prevention of influenza Not approved 24/09/2008 No Pegaptanib sodium AMD Not Approved 27/08/2008 No Telbivudine Hepatitis B Not approved 27/08/2008 No Carmustine (implant) Glioblastoma multiforme Not approved 25/06/2008 No Bevacizumab NSCLC Not approved 25/06/2008 No Infliximab Ankylosing spondylitis Not Approved 28/05/2008 No
Infliximab UC (sub-acute manifestations) Not Approved 23/04/2008 No Pemetrexed (2nd line) Not approved 22/08/2007 No Fludarabine phosphate CLL Not approved 28/02/2007 No Bevacizumab Adv./metastatic colorectal Ca TA118 Not approved 24/01/2007 No Cetuximab Metastatic colorectal Ca (2nd line) Not approved 24/01/2007 No Fluorouracil Colorectal Ca (metastatic) Not approved 24/01/2007 No Paclitaxel Early breast Ca Not approved 27/09/2006 No Efalizumab Psoriasis Market Authorisation withdrawn 26/07/2006 No Drotrecogin alfa Sepsis terminated No Temsirolimus Mantle cell lymphoma Terminated No